As an investor, it's smart to be skeptical when presented with a press release purporting to describe the results of a clinical study, particularly a small phase II study. But as I said above, Peregrine gets credit for running a controlled study of bavi, which definitely lends credibility to the data announced Tuesday. It will be interesting to see how the data hold up as the study matures and additional results are reported.
Peregrine is an interesting challenge to the "Feuerstein-Ratain Rule", which states that an oncology drug company's market value is inversely correlated to the risk of phase III clinical failure. Granted, bavi is still in phase II studies, but Peregrine's market value of under $100 million suggests bavi has little chance of success. That the drug's been around a long time and has never generated interest from partners also weighs against it.
"The only thing that gives me pause is that the study was not blinded. Other than that, I see no holes," said Dr. Mark Ratain, a professor and oncologist at the University of Chicago and the co-inventor of the "Feuerstein-Ratain Rule."
Adds Ratain: "This is truly a test of our rule since the publicly disclosed data look pretty solid!"
Patrick A emails, "Please blast Spectrum Pharmaceuticals' (SPPI) CEO, Raj Shrotriya. Please. I am a shareholder but I am absolutely sickened by the amount of compensation this guy receives. Yes, the stock has had a nice run, but assuming Shrotriya gets his 520,000-share award this month, the total amount of shares awarded to Shrotriya in 2011 will be 2.87 million shares. Yes, 2.87 million shares in either awards or options in a single calendar year! This in addition to a $1.9 million cash bonus! Am I wrong in considering this absolutely ridiculous? I am pissed off as a shareholder. The dude pays himself like he's running a multibillion-dollar large pharma with thousands of employees bringing in billions of revenue. Spectrum is a $800 million
John Paul writes, "I really don't know who the worst biotech CEO should be, but I pronounce you the winner in the homer
>To contact the writer of this article, click here: Adam Feuerstein. >To follow the writer on Twitter, go to http://twitter.com/adamfeuerstein. >To submit a news tip, send an email to: firstname.lastname@example.org. Follow TheStreet on Twitter and become a fan on Facebook.
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV